1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Asthma Treatment Market
4. Market Overview
    4.1. Introduction
        4.1.1. Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Asthma Treatment Market Analysis and Forecast, 2017–2031
        4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
    5.1. Key Industry Events (Mergers & Acquisitions, Treatment Type Launches, Partnerships, etc.)
    5.2. Pipeline Analysis
    5.3. Regulatory Scenario by Region/Globally
    5.4. COVID-19 Pandemic Impact on the Industry
6. Global Asthma Treatment Market Analysis and Forecast, by Treatment Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Treatment Type, 2017–2031
        6.3.1. Long-term Asthma Control Medications
        6.3.2. Quick-relief (Rescue) Medications
    6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Asthma Treatment Market Analysis and Forecast, by Route of Administration
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Route of Administration, 2017–2031
        7.3.1. Inhaled
        7.3.2. Oral
        7.3.3. Intravenous
        7.3.4. Subcutaneous
    7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Asthma Treatment Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Distribution Channel, 2017–2031
        8.3.1. Retail Pharmacies
        8.3.2. Hospital Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Asthma Treatment Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Asthma Treatment Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Treatment Type, 2017–2031
        10.2.1. Long-term Asthma Control Medications
        10.2.2. Quick-relief (Rescue) Medications
    10.3. Market Value Forecast, by Route of Administration, 2017–2031
        10.3.1. Inhaled
        10.3.2. Oral
        10.3.3. Intravenous
        10.3.4. Subcutaneous
    10.4. Market Value Forecast, by Distribution Channel, 2017–2031
        10.4.1. Retail Pharmacies
        10.4.2. Hospital Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Country, 2017–2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Treatment Type
        10.6.2. By Route of Administration
        10.6.3. By Distribution Channel
        10.6.4. By Country
11. Europe Asthma Treatment Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Treatment Type, 2017–2031
        11.2.1. Long-term Asthma Control Medications
        11.2.2. Quick-relief (Rescue) Medications
    11.3. Market Value Forecast, by Route of Administration, 2017–2031
        11.3.1. Inhaled
        11.3.2. Oral
        11.3.3. Intravenous
        11.3.4. Subcutaneous
    11.4. Market Value Forecast, by Distribution Channel, 2017–2031
        11.4.1. Retail Pharmacies
        11.4.2. Hospital Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Treatment Type
        11.6.2. By Route of Administration
        11.6.3. By Distribution Channel
        11.6.4. By Country/Sub-region
12. Asia Pacific Asthma Treatment Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Treatment Type, 2017–2031
        12.2.1. Long-term Asthma Control Medications
        12.2.2. Quick-relief (Rescue) Medications
    12.3. Market Value Forecast, by Route of Administration, 2017–2031
        12.3.1. Inhaled
        12.3.2. Oral
        12.3.3. Intravenous
        12.3.4. Subcutaneous
    12.4. Market Value Forecast, by Distribution Channel, 2017–2031
        12.4.1. Retail Pharmacies
        12.4.2. Hospital Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Treatment Type
        12.6.2. By Route of Administration
        12.6.3. By Distribution Channel
        12.6.4. By Country/Sub-region
13. Latin America Asthma Treatment Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Treatment Type, 2017–2031
        13.2.1. Long-term Asthma Control Medications
        13.2.2. Quick-relief (Rescue) Medications
    13.3. Market Value Forecast, by Route of Administration, 2017–2031
        13.3.1. Inhaled
        13.3.2. Oral
        13.3.3. Intravenous
        13.3.4. Subcutaneous
    13.4. Market Value Forecast, by Distribution Channel, 2017–2031
        13.4.1. Retail Pharmacies
        13.4.2. Hospital Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Treatment Type
        13.6.2. By Route of Administration
        13.6.3. By Distribution Channel
        13.6.4. By Country/Sub-region
14. Middle East & Africa Asthma Treatment Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Treatment Type, 2017–2031
        14.2.1. Long-term Asthma Control Medications
        14.2.2. Quick-relief (Rescue) Medications
    14.3. Market Value Forecast, by Route of Administration, 2017–2031
        14.3.1. Inhaled
        14.3.2. Oral
        14.3.3. Intravenous
        14.3.4. Subcutaneous
    14.4. Market Value Forecast, by Distribution Channel, 2017–2031
        14.4.1. Retail Pharmacies
        14.4.2. Hospital Pharmacies
        14.4.3. Online Pharmacies
    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Treatment Type
        14.6.2. By Route of Administration
        14.6.3. By Distribution Channel
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competition Matrix (by tier and size of companies)
    15.2. Market Share/Ranking Analysis, by Company (2021)
    15.3. Company Profiles
        15.3.1. Mylan N.V.
            15.3.1.1. Company Overview
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Strategic Overview
        15.3.2. AstraZeneca plc
            15.3.2.1. Company Overview
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Strategic Overview
        15.3.3. Boehringer Ingelheim
            15.3.3.1. Company Overview
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Strategic Overview
        15.3.4. F. Hoffmann-La Roche Ltd.
            15.3.4.1. Company Overview
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Strategic Overview
        15.3.5. GlaxoSmithKline plc.
            15.3.5.1. Company Overview
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Strategic Overview
        15.3.6. Glenmark Pharmaceuticals
            15.3.6.1. Company Overview
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Strategic Overview
        15.3.7. Lupin Pharmaceuticals
            15.3.7.1. Company Overview
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Strategic Overview
        15.3.8. Merck & Co. Inc.
            15.3.8.1. Company Overview
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Strategic Overview
        15.3.9. Novartis International AG
            15.3.9.1. Company Overview
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Strategic Overview
        15.3.10. Sanofi
            15.3.10.1. Company Overview
            15.3.10.2. Product Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Strategic Overview
        15.3.11. Sunovion Pharmaceuticals, Inc.
            15.3.11.1. Company Overview
            15.3.11.2. Product Portfolio
            15.3.11.3. SWOT Analysis
            15.3.11.4. Strategic Overview
        15.3.12. Teva Pharmaceutical Industries
            15.3.12.1. Company Overview
            15.3.12.2. Product Portfolio
            15.3.12.3. SWOT Analysis
            15.3.12.4. Strategic Overvie
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer



 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			